Hasanov, M., Kiany, S., Forget, M., Bassett, R., Davies, M. A., Diab, A., . . . Amaria, R. N. (2025). Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology, 14(1), 2546402. https://doi.org/10.1080/2162402X.2025.2546402
Chicago Style (17th ed.) CitationHasanov, Merve, et al. "Lymphodepletion, Tumor-infiltrating Lymphocytes, and High Versus Low Dose IL-2 Followed by Pembrolizumab in Patients with Metastatic Melanoma." Oncoimmunology 14, no. 1 (2025): 2546402. https://doi.org/10.1080/2162402X.2025.2546402.
MLA (9th ed.) CitationHasanov, Merve, et al. "Lymphodepletion, Tumor-infiltrating Lymphocytes, and High Versus Low Dose IL-2 Followed by Pembrolizumab in Patients with Metastatic Melanoma." Oncoimmunology, vol. 14, no. 1, 2025, p. 2546402, https://doi.org/10.1080/2162402X.2025.2546402.